Consolidation with Loncastuximab Tesirine for Large B-cell Lymphoma Patients in Partial Response after CART: Planned Interim Futility Analysis of a Phase II Trial | Synapse
March 3, 2026
Consolidation with Loncastuximab Tesirine for Large B-cell Lymphoma Patients in Partial Response after CART: Planned Interim Futility Analysis of a Phase II Trial
Key Points
Demonstrates therapeutic potential with loncastuximab tesirine in patients showing partial response.
Key evidence indicates efficacy and safety in a phase II trial for large-B-cell lymphoma within the target population.
Trial protocol includes planned interim futility analysis to assess treatment outcomes in patients after CART therapy.
Significance highlights potential advancements in treatment options for large-B-cell lymphoma patients.